Byers Auditorium, Genentech Hall, UCSF Mission Bay
4-5 PM, Thursday, May 11. Reception to follow
Gilead Sciences is a Bay Area titan, a life science leader known for its pipeline of antivirals and Hepatitis C therapeutics. Its CEO is John F. Milligan, PhD, a former UCSF postdoc, who joined the company in 1990 as its 32nd employee. Join us on May 11 when Barry Selick, Vice Chancellor for Business Development, Innovation and Partnerships at UCSF, will engage Milligan in a conversation touching on topics such as Milligan's career path from postdoc to CEO of a major biotech, his experience leading it, and how Gilead feeds its pipeline of innovation and develops new products. Brook Byers, a Founding Partner of Kleiner Perkins Caufield & Byers and a member of the UCSF Board of Overseers, will provide introductory remarks.
4:00 pm Introduction: Brook Byers, Partner, Kleiner Perkins Caufield & Byers
4:00-5:00 pm Remarks from John Milligan, Gilead Sciences, followed by audience Q&A and a conversation moderated by Barry Selick, UCSF
5:00-6:30 pm Reception
This event is hosted by UCSF and QB3.